Providing complex support in analytics and bioanalytics of large molecules, a BioPharma department’s capabilities help get more efficient drugs to patients and subsequently improve quality of life.

An essential part of QUINTA-ANALYTICA’s service portfolio, its BioPharma team offers comprehensive support via the testing of large, more complex pharmaceutical products such as peptides, proteins, monoclonal antibodies, and antibody-drug conjugates.

Led by Milan Madera, who has a strong background in characterization using chromatographic and mass spectrometric techniques, the dept. is equipped with modern high resolution/high mass accuracy LC-MS/MS, capillary electrophoresis designed for biopharma applications, and ELISA readers with a state-of-the-art MSD electrochemiluminescence platform which allows for immunogenicity testing of therapeutic drugs.

Despite being the newest dept. of Quinta, its operation in R&D, GMP, GLP, and GCP regimes help clients through the development and validations of methods not only for routine analysis of therapeutic products but also as bioanalytical support for preclinical and clinical testing.

If you’re looking for characterization of complex analytes or their quantification in various biological matrices, get in touch with Milan or the rest of the team today.

Additional News

  • 11 September 2025

    Meet us at CPHI 2025

    This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.

  • 8 September 2025

    Quinta-Analytica successfully passed two onsite FDA inspections

    In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).

  • 21 July 2025

    Boosting Bioanalytical Power for our clients

    New ICP-MS Expands Our Capabilities